Argenx's VYVGART® Hytrulo, a first-of-its-kind FcRn blocker, receives FDA approval for CIDP treatment.
Argenx received FDA approval for VYVGART® Hytrulo, a first-of-its-kind neonatal Fc receptor (FcRn) blocker, to treat chronic inflammatory demyelinating polyneuropathy (CIDP). Approved as a once-weekly subcutaneous injection, VYVGART® Hytrulo is the first novel, precision mechanism of action in over 30 years for CIDP patients and marks the third approved indication for VYVGART® and VYVGART Hytrulo franchise.
June 21, 2024
6 Articles